Insider Selling: Amicus Therapeutics, Inc. (FOLD) CFO Sells 10,000 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CFO William D. Baird III sold 10,000 shares of the business’s stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $15.63, for a total transaction of $156,300.00. Following the sale, the chief financial officer now owns 117,622 shares in the company, valued at $1,838,431.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Amicus Therapeutics opened at $16.13 on Friday, MarketBeat.com reports. Amicus Therapeutics, Inc. has a 52 week low of $10.18 and a 52 week high of $17.62. The company has a debt-to-equity ratio of 0.32, a quick ratio of 4.15 and a current ratio of 4.21.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.08. Amicus Therapeutics had a negative net margin of 563.98% and a negative return on equity of 60.09%. The business had revenue of $16.70 million for the quarter, compared to analyst estimates of $16.78 million. sell-side analysts predict that Amicus Therapeutics, Inc. will post -1.3 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in FOLD. Lord Abbett & CO. LLC purchased a new stake in shares of Amicus Therapeutics in the 1st quarter worth about $22,662,000. BlackRock Inc. boosted its position in shares of Amicus Therapeutics by 10.1% in the 1st quarter. BlackRock Inc. now owns 15,090,252 shares of the biopharmaceutical company’s stock worth $226,957,000 after buying an additional 1,378,155 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Amicus Therapeutics in the 4th quarter worth about $18,974,000. Sphera Funds Management LTD. boosted its position in shares of Amicus Therapeutics by 67.8% in the 1st quarter. Sphera Funds Management LTD. now owns 1,845,704 shares of the biopharmaceutical company’s stock worth $27,759,000 after buying an additional 745,704 shares in the last quarter. Finally, Redmile Group LLC boosted its position in shares of Amicus Therapeutics by 7.1% in the 1st quarter. Redmile Group LLC now owns 10,738,658 shares of the biopharmaceutical company’s stock worth $161,509,000 after buying an additional 712,888 shares in the last quarter.

Several equities research analysts have commented on FOLD shares. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 10th. ValuEngine upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. BidaskClub lowered shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 1st. Finally, Cowen restated a “buy” rating and set a $22.00 target price on shares of Amicus Therapeutics in a research report on Tuesday, May 8th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $19.06.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply